Anti-CD3 Fab Fragments Enhance Tumor Killing by Human γδ T Cells Independent of Nck Recruitment to the γδ T Cell Antigen Receptor
Claudia Juraske, Piyamaporn Wipa, Anna Morath, Jose Villacorta Hidalgo, Frederike A Hartl, Katrin Raute, Hans-Heinrich Oberg, Daniela Wesch, Paul Fisch, Susana Minguet, Sutatip Pongcharoen, Wolfgang W Schamel, Claudia Juraske, Piyamaporn Wipa, Anna Morath, Jose Villacorta Hidalgo, Frederike A Hartl, Katrin Raute, Hans-Heinrich Oberg, Daniela Wesch, Paul Fisch, Susana Minguet, Sutatip Pongcharoen, Wolfgang W Schamel
Abstract
T lymphocytes expressing the γδ T cell receptor (γδ TCR) can recognize antigens expressed by tumor cells and subsequently kill these cells. γδ T cells are indeed used in cancer immunotherapy clinical trials. The anti-CD3ε antibody UCHT1 enhanced the in vitro tumor killing activity of human γδ T cells by an unknown molecular mechanism. Here, we demonstrate that Fab fragments of UCHT1, which only bind monovalently to the γδ TCR, also enhanced tumor killing by expanded human Vγ9Vδ2 γδ T cells or pan-γδ T cells of the peripheral blood. The Fab fragments induced Nck recruitment to the γδ TCR, suggesting that they stabilized the γδ TCR in an active CD3ε conformation. However, blocking the Nck-CD3ε interaction in γδ T cells using the small molecule inhibitor AX-024 neither reduced the γδ T cells' natural nor the Fab-enhanced tumor killing activity. Likewise, Nck recruitment to CD3ε was not required for intracellular signaling, CD69 and CD25 up-regulation, or cytokine secretion by γδ T cells. Thus, the Nck-CD3ε interaction seems to be dispensable in γδ T cells.
Keywords: AX-024; Fab fragments; Nck; T cell antigen receptor; activation; signaling; tumor; γδ T cells.
Figures
References
- Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science (1998) 279:1737–40.10.1126/science.279.5357.1737
- Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, Lim RT, et al. CD1d-lipid antigen recognition by the γδ TCR. Nat Immunol (2013) 14:1137–45.10.1038/ni.2713
- Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol (2013) 13:88–100.10.1038/nri3384
- Chien Y, Konigshofer Y. Antigen recognition by γδ T cells. Immunol Rev (2007) 215:46–58.10.1111/j.1600-065X.2006.00470.x
- Bonneville M, O’Brien RL, Born WK. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol (2010) 10:467–78.10.1038/nri2781
- Zou C, Zhao P, Xiao Z, Han X, Fu F, Fu L. γδ T cells in cancer immunotherapy. Oncotarget (2017) 8:8900–9.10.18632/oncotarget.13051
- Chitadze G, Oberg HH, Wesch D, Kabelitz D. The ambiguous role of γδ T lymphocytes in antitumor immunity. Trends Immunol (2017) 38:668–78.10.1016/j.it.2017.06.004
- Bukowski JF, Morita CT, Band H, Brenner MB. Crucial role of TCR γ chain junctional region in prenyl pyrophosphate antigen recognition by γδ T cells. J Immunol (1998) 161:286–93.
- Bukowski JF, Morita CT, Tanaka Y, Bloom BR, Brenner MB, Band H. Vγ2Vδ2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J Immunol (1995) 154:998–1006.
- Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, et al. Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands. Science (1994) 264:267–70.10.1126/science.8146660
- Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature (1995) 375:155–8.10.1038/375155a0
- Espinosa E, Belmant C, Pont F, Luciani B, Poupot R, Romagne F, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γδ T cells. J Biol Chem (2001) 276:18337–44.10.1074/jbc.M100495200
- Fisch P, Meuer E, Pende D, Rothenfusser S, Viale O, Kock S, et al. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vγ9/Vδ2 T cells in tumor immunity. Eur J Immunol (1997) 27:3368–79.10.1002/eji.1830271236
- Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med (2003) 197:163–8.10.1084/jem.20021500
- Silva-Santos B, Serre K, Norell H. γδ T cells in cancer. Nat Rev Immunol (2015) 15:683–91.10.1038/nri3904
- Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K. Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol (2009) 144:245–50.10.1111/j.1365-2141.2008.07435.x
- Benzaid I, Monkkonen H, Bonnelye E, Monkkonen J, Clezardin P. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vgamma9Vdelta2 T-cell antitumor cytotoxicity through ICAM-1 engagement. Clin Cancer Res (2012) 18:6249–59.10.1158/1078-0432.CCR-12-0918
- Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human Vγ9Vδ2 γδ T cells in vitro and in SCID mice in vivo. J Immunol (2004) 173:6767–76.10.4049/jimmunol.173.11.6767
- Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res (2007) 67:7450–7.10.1158/0008-5472.CAN-07-0199
- Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose IL-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol (2010) 161:290–7.10.1111/j.1365-2249.2010.04167.x
- Oberg HH, Grage-Griebenow E, dam-Klages SA, Jerg E, Peipp M, Kellner C, et al. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. Pancreatology (2016) 16:1069–79.10.1016/j.pan.2016.07.008
- Oberg HH, Kellner C, Gonnermann D, Peipp M, Peters C, Sebens S, et al. γδ T cell activation by bispecific antibodies. Cell Immunol (2015) 296:41–9.10.1016/j.cellimm.2015.04.009
- Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, et al. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells. Cancer Res (2014) 74:1349–60.10.1158/0008-5472.CAN-13-0675
- Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol (2013) 14:908–16.10.1038/ni.2665
- Sandstrom A, Peigne CM, Leger A, Crooks JE, Konczak F, Gesnel MC, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity (2014) 40:490–500.10.1016/j.immuni.2014.03.003
- Gil D, Schamel WW, Montoya M, Sanchez-Madrid F, Alarcon B. Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational change essential for T cell receptor signaling and synapse formation. Cell (2002) 109:901–12.10.1016/S0092-8674(02)00799-7
- Swamy M, Beck-Garcia K, Beck-Garcia E, Hartl FA, Morath A, Yousefi OS, et al. A cholesterol-based allostery model of T cell receptor phosphorylation. Immunity (2016) 44:1091–101.10.1016/j.immuni.2016.04.011
- Schamel WW, Alarcon B, Hofer T, Minguet S. The allostery model of TCR regulation. J Immunol (2017) 198:47–52.10.4049/jimmunol.1601661
- Risueno RM, Gil D, Fernandez E, Sanchez-Madrid F, Alarcon B. Ligand-induced conformational change in the T-cell receptor associated with productive immune synapses. Blood (2005) 106:601–8.10.1182/blood-2004-12-4763
- Minguet S, Swamy M, Alarcon B, Luescher IF, Schamel WW. Full activation of the T cell receptor requires both clustering and conformational changes at CD3. Immunity (2007) 26:43–54.10.1016/j.immuni.2006.10.019
- Martínez-Martín N, Risueño RM, Morreale A, Zaldívar I, Fernández-Arenas E, Herranz F, et al. Cooperativity between T cell receptor complexes revealed by conformational mutants of CD3epsilon. Sci Signal (2009) 2:ra43.10.1126/scisignal.2000402
- Blanco R, Borroto A, Schamel WW, Pereira P, Alarcon B. Conformational changes in the T cell receptor differentially determine T cell subset development in mice. Sci Signal (2014) 7:ra115.10.1126/scisignal.2005650
- Paensuwan P, Hartl FA, Yousefi OS, Ngoenkam J, Wipa P, Beck-Garcia E, et al. Nck binds to the T cell antigen receptor using its SH3.1 and SH2 domains in a cooperative manner, promoting TCR functioning. J Immunol (2016) 196:448–58.10.4049/jimmunol.1500958
- Borroto A, Arellano I, Dopfer EP, Prouza M, Suchanek M, Fuentes M, et al. Nck recruitment to the TCR required for ZAP70 activation during thymic development. J Immunol (2013) 190:1103–12.10.4049/jimmunol.1202055
- Borroto A, Arellano I, Blanco R, Fuentes M, Orfao A, Dopfer EP, et al. Relevance of Nck-CD3epsilon interaction for T cell activation in vivo. J Immunol (2014) 192:2042–53.10.4049/jimmunol.1203414
- Borroto A, Reyes-Garau D, Jimenez MA, Carrasco E, Moreno B, Martinez-Pasamar S, et al. First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Sci Transl Med (2016) 8:370ra184.10.1126/scitranslmed.aaf2140
- Minguet S, Schamel WWA. A permissive geometry model for TCR-CD3 activation. Trends Biochem Sci (2008) 33:51–7.10.1016/j.tibs.2007.10.008
- Chang TW, Kung PC, Gingras SP, Goldstein G. Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells? Proc Natl Acad Sci U S A (1981) 78:1805–8.10.1073/pnas.78.3.1805
- Kaye J, Janeway CA, Jr. The Fab fragment of a directly activating monoclonal antibody that precipitates a disulfide-linked heterodimer from a helper T cell clone blocks activation by either allogeneic Ia or antigen and self-Ia. J Exp Med (1984) 159:1397–412.10.1084/jem.159.5.1397
- Cordoba SP, Choudhuri K, Zhang H, Bridge M, Basat AB, Dustin ML, et al. The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor. Blood (2013) 121:4295–302.10.1182/blood-2012-07-442251
- Dopfer EP, Hartl FA, Oberg HH, Siegers GM, Yousefi OS, Kock S, et al. The CD3 conformational change in the γδ T cell receptor is not triggered by antigens but can be enforced to enhance tumor killing. Cell Rep (2014) 7:1704–15.10.1016/j.celrep.2014.04.049
- Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods (2006) 3:995–1000.10.1038/nmeth947
- Alibaud L, Arnaud J, Llobera R, Rubin B. On the role of CD3δ chains in TCRγδ/CD3 complexes during assembly and membrane expression. Scand J Immunol (2001) 54:155–62.10.1046/j.1365-3083.2001.00938.x
- Siegers GM, Swamy M, Fernandez-Malave E, Minguet S, Rathmann S, Guardo AC, et al. Different composition of the human and the mouse γδ T cell receptor explains different phenotypes of CD3γ and CD3δ-immunodeficiencies. J Exp Med (2007) 204:2537–44.10.1084/jem.20070782102207c
- Siegers GM, Ribot EJ, Keating A, Foster PJ. Extensive expansion of primary human γδ T cells generates cytotoxic effector memory cells that can be labeled with Feraheme for cellular MRI. Cancer Immunol Immunother (2012) 62:571–83.10.1007/s00262-012-1353-y
- Wesch D, Marx S, Kabelitz D. Comparative analysis of alpha beta and γδ T cell activation by Mycobacterium tuberculosis and isopentenyl pyrophosphate. Eur J Immunol (1997) 27:952–6.10.1002/eji.1830270422
- Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, et al. Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy (2008) 10:842–56.10.1080/14653240802419328
- Crowley MP, Fahrer AM, Baumgarth N, Hampl J, Gutgemann I, Teyton L, et al. A population of murine γδ T cells that recognize an inducible MHC class Ib molecule. Science (2000) 287:314–6.10.1126/science.287.5451.314
- Adams EJ, Chien YH, Garcia KC. Structure of a γδ T cell receptor in complex with the nonclassical MHC T22. Science (2005) 308:227–31.10.1126/science.1106885
- Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med (2015) 21:938–45.10.1038/nm.3909
- Deniger DC, Moyes JS, Cooper LJ. Clinical applications of γδ T cells with multivalent immunity. Front Immunol (2014) 5:636.10.3389/fimmu.2014.00636
- Fournie JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagne F, et al. What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol (2013) 10:35–41.10.1038/cmi.2012.39
- Paul S, Lal G. Regulatory and effector functions of γδ T cells and their therapeutic potential in adoptive cellular therapy for cancer. Int J Cancer (2016) 139:976–85.10.1002/ijc.30109
- Courtney AH, Lo WL, Weiss A. TCR signaling: mechanisms of initiation and propagation. Trends Biochem Sci (2018) 43:108–23.10.1016/j.tibs.2017.11.008
- Lafont V, Liautard J, Sable-Techene M, Sainte-Marie Y, Favero J. Isopentenyl pyrophosphate, a mycobacterial non-peptidic antigen, triggers delayed and highly sustained signaling in human γδ T lymphocytes without inducing down-modulation of T cell antigen receptor. J Biol Chem (2001) 276:15961–7.10.1074/jbc.M008684200
- Correia DV, d’Orey F, Cardoso BA, Lanca T, Grosso AR, deBarros A, et al. Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human γδ T-cells. PLoS One (2009) 4:e5657.10.1371/journal.pone.0005657
- Nedellec S, Sabourin C, Bonneville M, Scotet E. NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals. J Immunol (2010) 185:55–63.10.4049/jimmunol.1000373
- Thedrez A, Sabourin C, Gertner J, Devilder MC, Allain-Maillet S, Fournie JJ, et al. Self/non-self discrimination by human γδ T cells: simple solutions for a complex issue? Immunol Rev (2007) 215:123–35.10.1111/j.1600-065X.2006.00468.x
- Cipriani B, Knowles H, Chen L, Battistini L, Brosnan CF. Involvement of classical and novel protein kinase C isoforms in the response of human Vγ9Vδ2 T cells to phosphate antigens. J Immunol (2002) 169:5761–70.10.4049/jimmunol.169.10.5761
Source: PubMed